Abstract
Infusion-Related Reactions With Ocrelizumab: Risk Factors, Symptom Management and Patient Choices in the ENSEMBLE PLUS Study (P7-3.003)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have